ChemoCentryx, Inc.

CHEMOCENTRYX

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;CHEMO CENTRIC;

CYTOTRAFFIC BARCODE

BARCODE;DRUG DEVELOPMENT AND DISCOVERY SERVICES, INCLUDING DETERMINING THE EFFECT OF CHEMOKINES ON CELL MIGRATION FOR MULTIPLE CELL TYPES;

DISPLACEMAX

DISPLACE MAX;RESEARCH AND DEVELOPMENT OF PHARMACEUTICAL PRODUCTS FOR OTHERS; RESEARCH AND DEVELOPMENT OF CHEMOKINE-BASED PHARMACEUTICAL PRODUCTS FOR OTHERS;

ENABALINK

Research and development of pharmaceutical products for others; research and development of chemokine-based pharmaceutical products for others;

LEUKOTRAFFIC BARCODE

LEUKOCYTE TRAFFIC BAR CODE;BARCODE;DRUG DEVELOPMENT AND DISCOVERY SERVICES, INCLUDING DETERMINING THE EFFECT OF CHEMOKINES ON CELL MIGRATION FOR MULTIPLE CELL TYPES;

ORPHANADOPT

ORPHAN ADOPT;Research and development of pharmaceutical products for others; research and development of chemokine-based pharmaceutical products for others;

PRODENDRYX

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS, AND SYNDROMES; CHEMOKINE-BASED PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES;

RAM

DRUG DEVELOPMENT AND SCREENING SERVICES, INCLUDING IDENTIFYING DRUG CANDIDATES, SUCH AS SCREENING FOR COMPOUNDS THAT INTERACT WITH CHEMOKINE RECEPTORS;

TAVNEOS

Pharmaceutical preparations for the treatment of autoimmune and inflammatory diseases;

TAVYLBY

Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory and autoimmune diseases, disorders and syndromes;

TRAFICET

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS, AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET

Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory and autoimmune diseases, disorders and syndromes, such as chemokine-mediated diseases;

TRAFICET-EN

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET-EN

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET-EN

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET-EN

PHARMACEUTICAL PREPARATIONS FOR USE IN THE TREATMENT OF HUMAN DISEASE, NAMELY, INFLAMMATORY AND AUTOIMMUNE DISEASES, DISORDERS AND SYNDROMES, SUCH AS CHEMOKINE-MEDIATED DISEASES;

TRAFICET-EN

Pharmaceutical preparations for use in the treatment of human disease, namely, inflammatory and autoimmune diseases, disorders and syndromes, such as chemokine-mediated diseases;

VYNPENTA

Pharmaceutical products for the treatment of autoimmune and inflammatory diseases;